Investigator Perspectives

Investigator Perspectives

Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.


Use of Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (AML)

June 22nd 2022

Courtney DiNardo, MD, discusses the use of venetoclax in newly-diagnosed acute myeloid leukemia, with a review of data from the VIALE-A clinical trial.

The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis

April 19th 2022

Naveen Pemmaraju, MD, provides his expert perspective on currently available treatment options in myelofibrosis and data from the REFINE trial on the experimental therapy of ruxolitinib plus navitoclax.

Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial Data

April 14th 2022

Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.

The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced RCC

March 18th 2022

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Moshe Ornstein, MD.

Endometrial Carcinoma Treatment Advances

January 14th 2022

Expert gynecologic oncologist Brian Slomovitz, MD, MS, FACOG, shares insight on novel therapeutic approaches to the management of endometrial cancer.

Novel Immune Checkpoint Inhibitors in Advanced Cervix Cancer

December 17th 2021

David M. O’Malley, MD, explores the use of PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of recurrent/metastatic cervical cancer.

Advanced/Metastatic Cholangiocarcinoma Treatment Landscape

December 3rd 2021

Expert perspective from Anthony B. El-Khoueiry, MD, who reviews the evolving treatment landscape of targeted therapy for advanced/metastatic cholangiocarcinoma.

The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

December 1st 2021

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.

Transarterial Yttrium-90 Radioembolization with Chemotherapy for the Treatment of Colorectal Liver Metastasis: The EPOCH Study

November 1st 2021

Mary F. Mulcahy, MD, breaks down the phase III EPOCH study and explains how it has affected the treatment of colorectal cancer with liver metastasis.

Prostate Cancer: The VISION Trial

October 19th 2021

Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).